<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363270</url>
  </required_header>
  <id_info>
    <org_study_id>2014-10-08-MMC</org_study_id>
    <nct_id>NCT02363270</nct_id>
  </id_info>
  <brief_title>Ketamine: Comparison of IV Push vs. IV Drip</brief_title>
  <official_title>Comparison of Intravenous Push Dose of Low Dose Ketamine to Short Infusion of Low Dose Ketamine for Treatment of Moderate to Severe Pain in the Emergency Department: A Prospective, Randomized, Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our previous published research comparing the efficacy of intravenous ketamine to morphine
      has shown ketamine to provide equivalent relief of moderate to severe acute pain in emergency
      medicine patients. Secondary analysis of the previous published research has also revealed
      ketamine to have statistically more side effects. The investigators believe that increasing
      the time of administration of the ketamine, from a push injection to a drip infusion, will
      minimize the side effects experienced by recipients of ketamine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketamine is a noncompetitive N-methyl D-aspartate (NMDA) receptor antagonist that blocks the
      release of excitatory neurotransmitter glutamate and provides anesthesia, amnesia and
      analgesia by virtue of decreasing central sensitization and &quot;wind-up&quot; phenomenon. At low
      (sub-dissociative, analgesics) doses of 0.1-0.4 mg/kg either as an adjunct to opioid
      analgesics or as a single agent, ketamine provides good analgesia while preserving airway
      patency, ventilation, and cardiovascular stability. In addition, the low-dose of ketamine
      increases the analgesic potency of opioids thus decreasing their requirements. Several recent
      studies of low-dose ketamine administered together with morphine provided acceptable pain
      relief to 55-60% of patients with minor side effects of dizziness, nausea and feeling of
      unreality. More recently the investigators conducted a research comparing Low-Dose Ketamine
      to Morphine for Moderate to Severe Pain in the Emergency Department with respect its
      analgesic efficacy and safety. Results demonstrated similar pain relief at 30 min between 2
      groups. However, 70% of patients in ketamine group had minor side effects at 5 min and 35% of
      patients at 30 min, as compared to 51% at 5 min. and 31% at 15 min. in the morphine group.
      The most common side effects reported by ketamine patients were dizziness, nausea, feeling of
      unreality, and mood changes.

      Based on the above mentioned data from our previous published research study, we hypothesized
      that low-dose ketamine given as a short infusion over 15 min will provide similar analgesic
      efficacy as an intravenous push-dose but with much less side effects. There are several
      research papers that support our hypothesis.

      A prospective, randomized trial compared two analgesic regimens, morphine with ketamine (K
      group) or morphine with placebo (P group) for severe acute pain in 73 trauma patients with a
      visual analog scale (VAS) score of at least 60/100. Morphine was administered at 0.1mg/kg and
      patients in the K group received 0.2 mg/kg of intravenous ketamine over 10 minutes, and the
      patients in the P group received isotonic sodium chloride solution. The results showed
      comparable change in VAS score at 30 minutes (34 mm (K) vs. 39 mm (P)) but reduced morphine
      consumption in the ketamine group (0.14 mg/kg (K) vs 0.2 mg/kg (P)).

      A double-blind trial of 40 adult patients with acute musculoskeletal trauma compared a
      low-dose ketamine by subcutaneous infusion (0.1 mg/kg/h) with intermittent morphine (0.1
      mg/kg IV every 4 hours ) and demonstrated better pain relief, less sedation and less nausea
      and vomiting with ketamine infusion than with intermittent morphine. In addition, none of the
      patients in ketamine group required supplementary analgesia.

      A prospective case series of 20 unselected adult ED patients with acute pain that evaluated
      analgesic feasibility of low-dose ketamine infusion was conducted in an urban public hospital
      over a course of 5 months. Patients received 15mg of intravenous push dose ketamine that was
      followed by continuous ketamine infusion at 20mg per hour for one hour. Optional morphine (4
      mg) was offered at 20, 40 and 60 minutes. Pain intensity was assessed at regular intervals
      for 2 hours using a 10-point verbal numerical rating scale (NRS), along with vital signs and
      levels of sedation. Results showed that fifteen patients reported clinically significant pain
      relief at 60 minutes and 13 at 120 minutes; and eighteen patients reported mild or modest
      side effects including dizziness, fatigue and headache.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">August 15, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Rate of Feeling Unreality</measure>
    <time_frame>30 minutes</time_frame>
    <description>Overall rate of feeling of unreality as measured by Side Effects Rating Scale for Dissociative Anesthetics (SERSDA)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>IV Push Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketamine medication given via IV Push. IV Push is the intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Drip Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketamine medication given via IV Drip. IV Drip is the intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>IV Push or or IV Drip</description>
    <arm_group_label>IV Push Group</arm_group_label>
    <arm_group_label>IV Drip Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Emergency Medicine patients

          -  Adult patients (18-65 years of age)

          -  Moderate to severe pain (Numeric Pain Rating Score =5).

          -  Patients must be awake, alert and oriented to time, place and person.

          -  Patients must be able to demonstrate understanding of the informed consent, and also
             able to verbalize how much pain they are having on the 10 point Numeric Rating Pain
             Scale, and the nature of the side effects they may be experiencing from the IV
             analgesia

        Exclusion Criteria:

          -  Patients with cognitive deficits that are not able to demonstrate understanding as
             described above.

          -  Patient's reported weight of less than 45kg or more than 115kg.

          -  Patients with altered mental status, alcohol intoxication, eye trauma.

          -  Patients with hemodynamic instability (Systolic Blood pressure &lt;90), and malignant
             hypertension.

          -  allergy to ketamine

          -  Pregnancy or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Marshall, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Fromm, MD</last_name>
    <role>Study Director</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>1. Abdullah M. Ketamine. A new look at an old drug. M ABDULLAH. anaesthetics.ukzn.ac.za/.../Ketamine_a_new_look_at_an_old_drug_...(accessed on 12/21/11)</citation>
  </reference>
  <reference>
    <citation>Javery KB, Ussery TW, Steger HG, Colclough GW. Comparison of morphine and morphine with ketamine for postoperative analgesia. Can J Anaesth. 1996 Mar;43(3):212-5.</citation>
    <PMID>8829857</PMID>
  </reference>
  <reference>
    <citation>Lester L, Braude DA, Niles C, Crandall CS. Low-dose ketamine for analgesia in the ED: a retrospective case series. Am J Emerg Med. 2010 Sep;28(7):820-7. doi: 10.1016/j.ajem.2009.07.023. Epub 2010 Apr 2.</citation>
    <PMID>20837262</PMID>
  </reference>
  <reference>
    <citation>Richards JR, Rockford RE. Low-dose ketamine analgesia: patient and physician experience in the ED. Am J Emerg Med. 2013 Feb;31(2):390-4. doi: 10.1016/j.ajem.2012.07.027. Epub 2012 Oct 4.</citation>
    <PMID>23041484</PMID>
  </reference>
  <reference>
    <citation>Gurnani A, Sharma PK, Rautela RS, Bhattacharya A. Analgesia for acute musculoskeletal trauma: low-dose subcutaneous infusion of ketamine. Anaesth Intensive Care. 1996 Feb;24(1):32-6.</citation>
    <PMID>8669651</PMID>
  </reference>
  <reference>
    <citation>Galinski M, Dolveck F, Combes X, Limoges V, Smaïl N, Pommier V, Templier F, Catineau J, Lapostolle F, Adnet F. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007 May;25(4):385-90.</citation>
    <PMID>17499654</PMID>
  </reference>
  <reference>
    <citation>Terence L. Ahern, Andrew A. Herring, Bradley W. Frazee. Alameda County Medical Center - Highland Hospital, Oakland, CA Safety And Efficacy Of Low-dose Ketamine Infusion For Emergency Department Patients With Acute Severe Pain</citation>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2015</study_first_posted>
  <results_first_submitted>March 18, 2017</results_first_submitted>
  <results_first_submitted_qc>May 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2017</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Research Manager</investigator_title>
  </responsible_party>
  <keyword>Analgesia</keyword>
  <keyword>ketamine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IV Push Group</title>
          <description>Ketamine medication given via IV Push. IV Push is the intervention.
Ketamine: IV Push or or IV Drip</description>
        </group>
        <group group_id="P2">
          <title>IV Drip Group</title>
          <description>Ketamine medication given via IV Drip. IV Drip is the intervention.
Ketamine: IV Push or or IV Drip</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IV Push Group</title>
          <description>Ketamine medication given via IV Push. IV Push is the intervention.
Ketamine: IV Push or or IV Drip</description>
        </group>
        <group group_id="B2">
          <title>IV Drip Group</title>
          <description>Ketamine medication given via IV Drip. IV Drip is the intervention.
Ketamine: IV Push or or IV Drip</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.25" spread="15.12"/>
                    <measurement group_id="B2" value="43.56" spread="12.32"/>
                    <measurement group_id="B3" value="44.40" spread="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Rate of Feeling Unreality</title>
        <description>Overall rate of feeling of unreality as measured by Side Effects Rating Scale for Dissociative Anesthetics (SERSDA)</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Push Group</title>
            <description>Ketamine medication given via IV Push. IV Push is the intervention.
Ketamine: IV Push or or IV Drip</description>
          </group>
          <group group_id="O2">
            <title>IV Drip Group</title>
            <description>Ketamine medication given via IV Drip. IV Drip is the intervention.
Ketamine: IV Push or or IV Drip</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Rate of Feeling Unreality</title>
          <description>Overall rate of feeling of unreality as measured by Side Effects Rating Scale for Dissociative Anesthetics (SERSDA)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>120 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IV Push Group</title>
          <description>Ketamine medication given via IV Push. IV Push is the intervention.
Ketamine: IV Push or or IV Drip</description>
        </group>
        <group group_id="E2">
          <title>IV Drip Group</title>
          <description>Ketamine medication given via IV Drip. IV Drip is the intervention.
Ketamine: IV Push or or IV Drip</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling of Unreality</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sergey Motov</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>718-283-8693</phone>
      <email>smotov@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

